Our study grants the analysis of a larger number of patients with MDS/AML under hypomethylating therapy or conventional care regimens to further support the observation that CDKN1C mRNA might help predict 5-azacytidine efficacy. This evidence concerns the gene CDKN1C and myelodysplastic syndrome.